// App-Quantinova.ai

P3-07-58 : CD44v as a potential predictive biomarker for pathologic complete response in primary HER2+ breast cancer: Utility of adaptive response biopsy in preoperative therapy

Researchers

Presenter

  • Yamauchi T

Principal Investigators

  • Imamura CK

  • Yamauchi H

  • Tripathy D

  • Zujewski JA

  • Chen H

  • Takebe N

  • Saya H

  • Ueno NT

  • Jinno H

  • Takahashi M

  • Kitagawa Y

  • Nakamura S

  • Lim B

  • Krishnamurthy S

  • Reuben JM

  • Liu D

Medical Centers

  • The Jikei University School of Medicine, Tokyo, Japan

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Division of Medical Oncology, St. Luke's International Hospital, Tokyo, Japan

  • St.Luke's International Hospital, Tokyo, Japan

  • Division of Gene Regulation, Institute for Advanced Medical Research, School of Medicine, Keio Unive, Tokyo, Japan

  • Keio University School of Medicine, Yokohama, Japan

  • Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD

Locations

  • United States

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Phosphorylated endothelial growth factor receptor

  • Phosphorylated HER2

  • Phosphorylated-extracellular signal regulated kinase

  • Circulating tumor cells

  • Cluster of Differentiation 44

  • Epidermal growth factor receptor

  • Extracellular signal-regulated kinase

  • Snail Family Transcriptional Repressor 1

  • Solute Carrier Family 22 Member 3

  • Twist-related protein 1

  • Zinc finger E-box binding homeobox 1

Drug/Treatment

  • Trastuzumab

  • Paclitaxel

  • Lapatinib

Outcome

  • N/A

Study Design

  • adaptive

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved